Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 10, Number 1—January 2004

Research

Fluoroquinolones Protective against Cephalosporin Resistance in Gram-negative Nosocomial Pathogens

Mitchell J. Schwaber*1Comments to Author , Sara E. Cosgrove*2, Howard S. Gold*, Keith S. Kaye†, and Yehuda Carmeli*‡
Author affiliations: *Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA; †Duke University Medical Center, Durham, North Carolina, USA; ‡Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Main Article

Table 2

Multivariable analysis of outcomea

Characteristic HR (95% CI)b p
Surgery during risk period 1.62 (1.16 to 2.25) 0.005
In intensive care unit during risk period 2.17 (1.49 to 3.16) <0.001
Receipt of β-lactam/β-lactamase inhibitor 2.52 (1.67 to 3.80) <0.001
Receipt of ureidopenicillin 2.55 (1.43 to 4.53) 0.002
Receipt of 3rd-generation cephalosporin 2.84 (1.89 to 4.27) <0.001
Receipt of fluoroquinolone 0.40 (0.21 to 0.76) 0.005

aOutcome refers to the isolation of third-generation cephalosporin-resistant Enterobacter spp., Pseudomonas aeruginosa, or Klebsiella pneumoniae from a clinical specimen.
bHR, hazard ratio; CI, confidence interval.

Main Article

1Current affiliation: Epidemiology Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

2Current affiliation: Division of Infectious Disease, Johns Hopkins Hospital, Baltimore, Maryland, USA.

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO